{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:07:02Z","timestamp":1784052422080,"version":"3.55.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This retrospective study in patients with neuroendocrine liver metastases analyzes baseline vascularity on MR as a predictor of tumour debulking after conventional Yttrium-90 transarterial radioembolization (TARE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>30 patients who underwent TARE at our center between 2015 and 2022 were retrospectively assessed. Pre- and post-treatment target lesion volumes were measured as total tumor volume (TTV) and enhancing tumor volume (ETV). Cox-regression analyses as well as Kaplan-Meier statistics were used to evaluate baseline volumetric imaging parameters and clinical variables as predictors of survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean patients\u2019 age was 63 (SD 11) years, 15 were female (50%). The primary tumor was in the upper gastrointestinal tract in 13\/30 cases (43%). Median overall survival (mOS) was 33.0 months (95%CI [21.2; 44.7]). Eligibility for peptide receptor radionuclide therapy (PRRT) was the single strongest predictor of survival with a hazard ratio of 0.22 (p\u2009=\u20090.024) and a mOS of 60.8 months whereas receptor-negative patients had the shortest survival of 7.0 months (p\u2009=\u20090.019). A baseline ETV\/TTV ratio greater 50% was associated with a decrease in median ETV by 41% after lobar TARE compared to an increase by 18% in patients with poor baseline vascularity (p\u2009=\u20090.018). In the 17\/30 patient who received systemic therapies exclusively before TARE, mOS was 15 vs. 6.8 months (p\u2009=\u20090.082). Prior PRRT did not significantly impact the change of ETV after TARE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In lobar TARE for neuroendocrine liver metastases, high baseline vascularity shows an exploratory association with a significant reduction in viable tumor volume, warranting further investigation to improve patient selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0352018","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:27:01Z","timestamp":1784050021000},"page":"e0352018","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Yttrium-90 radioembolization for neuroendocrine liver metastases: baseline vascularity predicts cytoreduction efficacy"],"prefix":"10.1371","volume":"21","author":[{"given":"Anne","family":"Frisch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Collettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Steinhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uli","family":"Fehrenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Amthauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imke","family":"Schatka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Herzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gero","family":"Wieners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4255-1009","authenticated-orcid":true,"given":"Willie M.","family":"L\u00fcdemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"issue":"5","key":"pone.0352018.ref001","first-page":"679","article-title":"90Y Radioembolization in the treatment of neuroendocrine neoplasms: results of an international multicenter retrospective study","volume":"63","author":"BM Schaarschmidt","year":"2022","journal-title":"J Nucl Med"},{"issue":"18","key":"pone.0352018.ref002","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"JC Yao","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"pone.0352018.ref003","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11864-020-00751-x","article-title":"Interventional liver-directed therapy for neuroendocrine metastases: current status and future directions","volume":"21","author":"D D\u2019Souza","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"pone.0352018.ref004","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000475526","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues","volume":"105","author":"RJ Hicks","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"9","key":"pone.0352018.ref005","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1245\/s10434-020-08787-x","article-title":"The landmark series: neuroendocrine tumor liver metastases","volume":"27","author":"A Gangi","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"pone.0352018.ref006","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/bjs.6468","article-title":"Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease","volume":"96","author":"A Frilling","year":"2009","journal-title":"Br J Surg"},{"issue":"12","key":"pone.0352018.ref007","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1007\/s11864-023-01152-6","article-title":"Liver-directed therapy for neuroendocrine tumor metastases in the era of peptide receptor radionuclide therapy","volume":"24","author":"R Rabei","year":"2023","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"pone.0352018.ref008","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12885-022-09302-z","article-title":"Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry","volume":"22","author":"TY Wong","year":"2022","journal-title":"BMC Cancer"},{"issue":"12","key":"pone.0352018.ref009","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jvir.2019.06.003","article-title":"Radioembolization-induced chronic hepatotoxicity: a single-center cohort analysis","volume":"30","author":"BM Currie","year":"2019","journal-title":"J Vasc Interv Radiol"},{"issue":"11","key":"pone.0352018.ref010","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1007\/s00270-022-03206-y","article-title":"Role of radioembolization in metastatic neuroendocrine tumors","volume":"45","author":"RJ Lewandowski","year":"2022","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"2","key":"pone.0352018.ref011","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1148\/radiol.12112544","article-title":"Interventional oncologic approaches to liver metastases","volume":"266","author":"AH Mahnken","year":"2013","journal-title":"Radiology"},{"issue":"2","key":"pone.0352018.ref012","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2967\/jnumed.123.266211","article-title":"Long-term overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: updated analysis of DOSISPHERE-01 trial","volume":"65","author":"E Garin","year":"2024","journal-title":"J Nucl Med"},{"issue":"1","key":"pone.0352018.ref013","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","volume":"6","author":"E Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"pone.0352018.ref014","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/MNM.0000000000000887","article-title":"Correlation of radiation dose and activity with clinical outcomes in metastatic colorectal cancer after selective internal radiation therapy using yttrium-90 resin microspheres","volume":"39","author":"S Badiyan","year":"2018","journal-title":"Nucl Med Commun"},{"issue":"8","key":"pone.0352018.ref015","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2967\/jnumed.118.219691","article-title":"Quantitative imaging biomarkers for 90y distribution on bremsstrahlung SPECT after resin-based radioembolization","volume":"60","author":"I Schobert","year":"2019","journal-title":"J Nucl Med"},{"issue":"1","key":"pone.0352018.ref016","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.diii.2023.06.007","article-title":"Neuroendocrine liver metastases treated using transarterial radioembolization: identification of prognostic parameters at 68Ga-DOTATATE PET\/CT","volume":"105","author":"M Ingenerf","year":"2024","journal-title":"Diagn Interv Imaging"},{"key":"pone.0352018.ref017","doi-asserted-by":"crossref","first-page":"553808","DOI":"10.2147\/JHC.S553808","article-title":"Lobar Yttrium-90 radioembolization with bsa-based dosimetry for unresectable hepatocellular carcinoma: baseline vascularity predicts responders to the combination with targeted therapy or immune checkpoint inhibition","volume":"12","author":"WM L\u00fcdemann","year":"2026","journal-title":"J Hepatocell Carcinoma"},{"issue":"3","key":"pone.0352018.ref018","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1148\/radiol.14140033","article-title":"Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis","volume":"273","author":"J Chapiro","year":"2014","journal-title":"Radiology"},{"issue":"7","key":"pone.0352018.ref019","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00330-015-3595-5","article-title":"Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver","volume":"25","author":"J Chapiro","year":"2015","journal-title":"Eur Radiol"},{"issue":"7","key":"pone.0352018.ref020","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1007\/s00330-022-08585-x","article-title":"Yttrium-90 radioembolization for unresectable hepatocellular carcinoma: predictive modeling strategies to anticipate tumor response and improve patient selection","volume":"32","author":"WM L\u00fcdemann","year":"2022","journal-title":"Eur Radiol"},{"key":"pone.0352018.ref021","article-title":"Management of neuroendocrine tumours","author":"K Oberg","year":"2004","journal-title":"Ann Oncol"},{"issue":"10446","key":"pone.0352018.ref022","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2011dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"S Singh","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"pone.0352018.ref023","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"J Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0352018.ref024","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jvir.2019.06.003","article-title":"Radioembolization-induced chronic hepatotoxicity: a single-center cohort analysis","volume":"30","author":"BM Currie","year":"2019","journal-title":"J Vasc Interv Radiol"},{"issue":"6","key":"pone.0352018.ref025","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jvir.2018.02.002","article-title":"Long-term toxicity after transarterial radioembolization with yttrium-90 using resin microspheres for neuroendocrine tumor liver metastases","volume":"29","author":"Y Tomozawa","year":"2018","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"pone.0352018.ref026","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1245\/s10434-020-09469-4","article-title":"Chemoembolization versus radioembolization for neuroendocrine liver metastases: a meta-analysis comparing clinical outcomes","volume":"28","author":"L Ngo","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"pone.0352018.ref027","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1007\/s00270-022-03209-9","article-title":"Analysis of tumor burden as a biomarker for patient survival with neuroendocrine tumor liver metastases undergoing intra-arterial therapies: a single-center retrospective analysis","volume":"45","author":"M Miszczuk","year":"2022","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"12","key":"pone.0352018.ref028","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high\u2011dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"JR Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"pone.0352018.ref029","doi-asserted-by":"crossref","first-page":"108834","DOI":"10.1016\/j.surg.2024.06.065","article-title":"Surgery enhances the effectiveness of peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumors","volume":"177","author":"J Tobias","year":"2025","journal-title":"Surgery"},{"issue":"5","key":"pone.0352018.ref030","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.crad.2024.01.014","article-title":"Local recurrence following a complete radiologic response in hepatocellular carcinoma patients: comparison of transarterial chemoembolisation and transarterial radioembolisation","volume":"79","author":"S Young","year":"2024","journal-title":"Clin Radiol"},{"issue":"3","key":"pone.0352018.ref031","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1002\/cam4.5125","article-title":"TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis","volume":"12","author":"AM Brown","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"pone.0352018.ref032","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00270-023-03614-8","article-title":"Integrated capecitabine-temozolomide with radioembolization for liver-dominant G2 NETs: long-term outcomes of a single-institution retrospective study","volume":"47","author":"MC Soulen","year":"2024","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"pone.0352018.ref033","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s11154-021-09647-z","article-title":"\u201cPresent and future of immunotherapy in Neuroendocrine Tumors\u201d","volume":"22","author":"M Albertelli","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"pone.0352018.ref034","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvir.2024.11.012","article-title":"Combining radioembolization and immune checkpoint inhibitors for the treatment of hepatocellular carcinoma: the quest for synergy","volume":"36","author":"CD Malone","year":"2025","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"pone.0352018.ref035","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s11684-023-0993-y","article-title":"Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial","volume":"17","author":"EAT Koch","year":"2023","journal-title":"Front Med"},{"key":"pone.0352018.ref036","unstructured":"Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases. https:\/\/clinicaltrials.gov\/study\/NCT03457948"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:27:19Z","timestamp":1784050039000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352018"}},"subtitle":[],"editor":[{"given":"Carmelo","family":"Caldarella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0352018","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}